Champions Oncology Reports Q1 2027 Earnings: Revenue Growth, Improved Margins
Champions Oncology (CSBR) reported first-quarter fiscal year 2027 results showing revenue of $15.2 million, an 8.8% increase from the prior-year period driven by improved conversion rates and higher data licensing income. The company achieved positive adjusted EBITDA for a fifth consecutive quarter at $671,000 compared to $59,000 in Q1 2026. Oncology services margin rose to 51% from 43%, attributed to lower third-party radiolabeling costs and better revenue leverage. Despite a net loss of $426,000 due largely to noncash expenses like stock-based compensation ($766,000), the company maintained strong cash balances at $4.4 million as it remained debt-free. Management highlighted strategic progress in transitioning radiolabeling work in-house and expanding data licensing revenue beyond previous fiscal year totals. CEO Robert Brainin emphasized the value of deeply characterized patient data for machine learning applications, while noting ongoing discussions to secure external funding for Corellia.
Tickers: $CSBR
Topics: adjusted_ebitda expenses net_loss revenue